A MicroRNA Profile for Androgen Responsive Prostate Cancer
Description of Invention:
This invention describes a microRNA gene expression profile in prostate cancers that correlates with androgen responsiveness. Most prostate cancers are androgen sensitive and can be treated with anti-androgen therapies. Tumors non-responsive to anti-androgen therapy are more aggressive and needs alternative therapeutic interventions. Additionally, the microRNAs discovered can also be potential targets for developing new prostate cancer drugs.
Applications:
MicroRNA expression profile can help physicians take informed treatment action on an individual basis.
Advantages: In vitro proof-of-concept data available.
Inventors:
Dr. Chang Hee Kim et al. (NCI)
Patent Status:
DHHS Reference No. E-142-2007/0 --
U.S. Provisional Application No. 60/906,742 filed 12 Mar 2007
PCT Application No. PCT/US2008/003346 filed 12 Mar 2008
Relevant Publication: A manuscript directly related to this technology will be available as soon as it is accepted for publication.
Licensing Status: Available for exclusive and non-exclusive licensing.
Collaborative Research Opportunity:
The NCI/SAIC-Frederick, Advanced Technology Program, Laboratory for Molecular Technology, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize microRNA diagnostic markers in cancer. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
Portfolios: Cancer
Cancer -Diagnostics-In Vitro-DNA Based Cancer -Diagnostics-In Vitro-Other Cancer -Diagnostics
For Additional Information Please Contact: Surekha Vathyam Ph.D.
Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301/435-4076
Email: vathyams@mail.nih.gov
Fax: 301/402-0220
